IN2014MN00357A - - Google Patents
Info
- Publication number
- IN2014MN00357A IN2014MN00357A IN357MUN2014A IN2014MN00357A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A IN 357MUN2014 A IN357MUN2014 A IN 357MUN2014A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A
- Authority
- IN
- India
- Prior art keywords
- hydrophobic
- peptides
- peptide
- yrfli
- irfli
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161528804P | 2011-08-30 | 2011-08-30 | |
| GBGB1115014.1A GB201115014D0 (en) | 2011-08-30 | 2011-08-30 | Peptides |
| GBGB1211740.4A GB201211740D0 (en) | 2012-07-03 | 2012-07-03 | Peptides |
| PCT/GB2012/052116 WO2013030569A2 (fr) | 2011-08-30 | 2012-08-29 | Peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00357A true IN2014MN00357A (fr) | 2015-06-19 |
Family
ID=47756980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN357MUN2014 IN2014MN00357A (fr) | 2011-08-30 | 2012-08-29 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9302014B2 (fr) |
| EP (1) | EP2751128B1 (fr) |
| JP (1) | JP6077543B2 (fr) |
| CN (1) | CN103998458B (fr) |
| AU (1) | AU2012300633B2 (fr) |
| BR (1) | BR112014004902B1 (fr) |
| CA (1) | CA2846218C (fr) |
| ES (1) | ES2876939T3 (fr) |
| IN (1) | IN2014MN00357A (fr) |
| WO (1) | WO2013030569A2 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015204452A1 (en) | 2014-01-13 | 2016-08-11 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
| WO2015188020A1 (fr) * | 2014-06-06 | 2015-12-10 | Vivoscript, Inc. | Méthode de réparation de lésion cartilagineuse |
| CN106397606B (zh) * | 2015-01-28 | 2020-11-10 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为sst药物载体的应用、方法及其融合蛋白复合物 |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| CN116196388A (zh) * | 2016-01-06 | 2023-06-02 | 康德生物医疗有限公司 | 用于预防和治疗杜氏肌肉萎缩症的方法和组合物 |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| MX2018013157A (es) | 2016-04-29 | 2019-05-23 | Sarepta Therapeutics Inc | Analogos de oligonucleotidos dirigidos a lmna humana. |
| US11021514B2 (en) | 2016-06-01 | 2021-06-01 | Athira Pharma, Inc. | Compounds |
| MX2018016253A (es) | 2016-07-05 | 2019-09-09 | Biomarin Tech Bv | Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos. |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Nrf2路徑的新穎化合物 |
| CA3078504A1 (fr) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | Inhibiteurs peptidiques bicycliques |
| CN108070025B (zh) * | 2017-10-24 | 2019-11-19 | 中山大学附属口腔医院 | 一种细胞穿透肽和细胞穿透肽复合物及二者的应用 |
| WO2019148195A2 (fr) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Inhibiteurs peptidyliques cycliques du domaine de liaison cal-pdz |
| JP2021521794A (ja) * | 2018-04-26 | 2021-08-30 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
| WO2019226651A1 (fr) * | 2018-05-22 | 2019-11-28 | Children's Medical Center Corporation | Nanoparticules pour le traitement de la néovascularisation choroïdienne et d'autres indications |
| GB201812980D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US12465646B2 (en) | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| CN113660938A (zh) * | 2019-01-30 | 2021-11-16 | 国立研究开发法人国立精神·神经医疗研究中心 | 核酸递送复合物 |
| GB201911403D0 (en) * | 2019-08-09 | 2019-09-25 | Univ Oxford Innovation Ltd | Conjugate and uses thereof |
| WO2022192749A2 (fr) * | 2021-03-12 | 2022-09-15 | Pepgen Inc. | Méthodes de traitement de la dystrophie musculaire de duchenne à l'aide de conjugués peptide-oligonucléotide |
| IL310185A (en) | 2021-07-16 | 2024-03-01 | Academisch Ziekenhuis Leiden | Oligonucleotide for inhibiting quaking activity |
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| IL316802A (en) | 2022-05-06 | 2025-01-01 | Academisch Ziekenhuis Leiden | Oligonucleotide |
| GB202216207D0 (en) * | 2022-11-01 | 2022-12-14 | Univ Oxford Innovation Ltd | Shortened cell-penetrating peptides |
| GB202411696D0 (en) | 2024-08-08 | 2024-09-25 | Univ Oxford Innovation Ltd | Therapeutic nucleic acids for treating genetic disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766489B2 (en) | 1998-11-13 | 2003-10-16 | Cyclacel Limited | Transport vectors |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| WO2009005793A2 (fr) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Conjugués peptidiques spécifiques d'un tissu et procédés |
| WO2009144481A2 (fr) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugués pour la délivrance de composés biologiquement actifs |
| WO2009147368A1 (fr) | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| WO2011064552A1 (fr) | 2009-11-30 | 2011-06-03 | Isis Innovation Limited | Conjugués destinés à libérer des composés biologiquement actifs |
-
2012
- 2012-08-29 CN CN201280042628.7A patent/CN103998458B/zh active Active
- 2012-08-29 JP JP2014527734A patent/JP6077543B2/ja active Active
- 2012-08-29 IN IN357MUN2014 patent/IN2014MN00357A/en unknown
- 2012-08-29 ES ES12756546T patent/ES2876939T3/es active Active
- 2012-08-29 WO PCT/GB2012/052116 patent/WO2013030569A2/fr not_active Ceased
- 2012-08-29 AU AU2012300633A patent/AU2012300633B2/en active Active
- 2012-08-29 BR BR112014004902-5A patent/BR112014004902B1/pt active IP Right Grant
- 2012-08-29 EP EP12756546.3A patent/EP2751128B1/fr active Active
- 2012-08-29 CA CA2846218A patent/CA2846218C/fr active Active
- 2012-08-29 US US14/240,832 patent/US9302014B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013030569A2 (fr) | 2013-03-07 |
| BR112014004902B1 (pt) | 2022-02-08 |
| US20140342992A1 (en) | 2014-11-20 |
| CA2846218A1 (fr) | 2013-03-07 |
| JP6077543B2 (ja) | 2017-02-08 |
| ES2876939T3 (es) | 2021-11-15 |
| JP2014526238A (ja) | 2014-10-06 |
| CN103998458B (zh) | 2018-10-09 |
| AU2012300633B2 (en) | 2017-04-27 |
| AU2012300633A8 (en) | 2014-05-29 |
| EP2751128A2 (fr) | 2014-07-09 |
| CA2846218C (fr) | 2020-09-01 |
| WO2013030569A3 (fr) | 2013-06-13 |
| EP2751128B1 (fr) | 2021-03-03 |
| US9302014B2 (en) | 2016-04-05 |
| AU2012300633A1 (en) | 2014-03-06 |
| CN103998458A (zh) | 2014-08-20 |
| BR112014004902A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00357A (fr) | ||
| NZ704192A (en) | Cell-penetrating peptides and uses therof | |
| BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
| MX344219B (es) | Productos farmaceuticos peptidicos mejorados para resistencia a insulina. | |
| EP3756690A3 (fr) | Peptides de pénétration membranaire destinés à améliorer la transfection, et leurs compositions et procédés d'utilisation | |
| WO2012158964A3 (fr) | Substances pharmaceutiques peptidiques améliorées servant à lutter contre l'ostéoporose | |
| WO2013104804A3 (fr) | Complémentation fonctionnelle bipartite induite par un antigène double | |
| MX360816B (es) | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. | |
| EP2570430A3 (fr) | Vaccins de peptide avec Seq ID No: 78, 41, 44, 46 or 48 pour cancers exprimant des antigènes associés aux tumeurs | |
| WO2012012352A3 (fr) | Peptides et protéines modifiés | |
| NZ629394A (en) | Synthetic brassica-derived chloroplast transit peptides | |
| JP2014224126A5 (fr) | ||
| MX2009013325A (es) | Transfeccion y transduccion de plantas con base en nano acarreadores. | |
| MX2009007070A (es) | Moleculas de transporte que utilizan los polipeptidos hiv-tat de secuencia inversa. | |
| WO2011135222A3 (fr) | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles | |
| WO2014134509A3 (fr) | Particules de glucane modifiées par un peptide et une amine pour la délivrance de charges thérapeutiques | |
| IN2014DN09963A (fr) | ||
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| MX365599B (es) | Moleculas de transporte especificas de proteoglicano c4s. | |
| MX2010005816A (es) | Epítopos de péptido de stat3. | |
| GB201205512D0 (en) | Active site probes | |
| MY151307A (en) | Peptides having antimicrobial activity | |
| SG10201809464RA (en) | Antibody gene expression-secretion system | |
| NZ603379A (en) | Ect2 peptides and vaccines including the same | |
| JP2011512364A5 (fr) |